RU2357969C2 - Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе - Google Patents

Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе Download PDF

Info

Publication number
RU2357969C2
RU2357969C2 RU2006109474/04A RU2006109474A RU2357969C2 RU 2357969 C2 RU2357969 C2 RU 2357969C2 RU 2006109474/04 A RU2006109474/04 A RU 2006109474/04A RU 2006109474 A RU2006109474 A RU 2006109474A RU 2357969 C2 RU2357969 C2 RU 2357969C2
Authority
RU
Russia
Prior art keywords
alkyl
pyridyl
xanthine
compound according
aryl
Prior art date
Application number
RU2006109474/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2006109474A (ru
Inventor
Гоцюань ВАНГ (US)
Гоцюань ВАНГ
Джейсон М. РИГЕР (US)
Джейсон М. Ригер
Роберт Д. ТОМПСОН (US)
Роберт Д. Томпсон
Original Assignee
АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи filed Critical АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи
Publication of RU2006109474A publication Critical patent/RU2006109474A/ru
Application granted granted Critical
Publication of RU2357969C2 publication Critical patent/RU2357969C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2006109474/04A 2003-08-25 2004-08-20 Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе RU2357969C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49787503P 2003-08-25 2003-08-25
US60/497,875 2003-08-25

Publications (2)

Publication Number Publication Date
RU2006109474A RU2006109474A (ru) 2007-10-10
RU2357969C2 true RU2357969C2 (ru) 2009-06-10

Family

ID=34272616

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006109474/04A RU2357969C2 (ru) 2003-08-25 2004-08-20 Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе

Country Status (19)

Country Link
US (3) US7342006B2 (Direct)
EP (2) EP2295434B1 (Direct)
JP (1) JP4769721B2 (Direct)
KR (1) KR101222364B1 (Direct)
CN (2) CN101851238B (Direct)
AR (1) AR045499A1 (Direct)
AU (1) AU2004268964B2 (Direct)
BR (1) BRPI0413922B8 (Direct)
CA (1) CA2536553C (Direct)
DK (2) DK1658291T3 (Direct)
ES (2) ES2557310T3 (Direct)
IL (1) IL173723A (Direct)
NZ (1) NZ545715A (Direct)
PL (1) PL1658291T3 (Direct)
PT (1) PT1658291E (Direct)
RU (1) RU2357969C2 (Direct)
TW (1) TWI362390B (Direct)
WO (1) WO2005021548A2 (Direct)
ZA (1) ZA200602333B (Direct)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532062A (en) * 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
KR20040080939A (ko) * 2002-02-01 2004-09-20 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 8-헤테로아릴 크산틴 아데노신 에이투비 수용체 길항제
PT1658291E (pt) * 2003-08-25 2013-10-21 Dogwood Pharmaceuticals Inc 8-heteroarilxantinas substituídas
SG155182A1 (en) * 2004-08-02 2009-09-30 Univ Virginia 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
AR051094A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
JP4958785B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003330A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
CA2580844A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
EP2540296A1 (en) 2005-06-03 2013-01-02 Xenon Pharmaceuticals Inc. Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CN101198608B (zh) * 2005-06-16 2011-04-27 吉利德帕洛阿尔托股份有限公司 A2b腺苷受体拮抗剂的前药
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
US7812025B2 (en) 2005-08-12 2010-10-12 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
US20070059740A1 (en) * 2005-08-26 2007-03-15 Linden Joel M Method of targeting a2b adenosine receptor antagonist therapy
US7566401B2 (en) * 2005-10-03 2009-07-28 Kelm Mark A Process for separating and isolating xanthines, individual polar protic monomers, and polar protic oligomers
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
WO2007149277A2 (en) 2006-06-16 2007-12-27 Pgx Health, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8193200B2 (en) * 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
RU2344137C1 (ru) * 2007-07-18 2009-01-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Производные 8-амино-7-(2-гидроксипропил-1)-1,3-диметилксантина гидрохлорида, проявляющие гемореологическую активность
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
BRPI0909157A2 (pt) 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
JP2011528364A (ja) * 2008-07-16 2011-11-17 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド アテローム性動脈硬化症の治療
BRPI1009398A2 (pt) 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
RU2404181C1 (ru) * 2009-06-02 2010-11-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) 3-метил-8-пиперазино-7-(тиетанил-3)-1-этилксантина гидрохлорид, проявляющий антиагрегационную и дезагрегационную активность
WO2011005871A1 (en) 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
US8796290B2 (en) 2009-11-09 2014-08-05 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
CN103261200B (zh) 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
EP2465859A1 (en) * 2010-12-08 2012-06-20 Life & Brain GmbH 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists
CN102532137B (zh) * 2011-12-05 2014-12-10 辽宁医学院 8-吡唑取代黄嘌呤类a2b腺苷受体拮抗剂及其合成方法和应用
EP3389664A4 (en) 2015-12-14 2020-01-08 Raze Therapeutics Inc. MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
US20230144283A1 (en) * 2020-03-26 2023-05-11 Inspyr Therapeutics,Inc. 8-substituted diaryl xanthines as dual a2a-a2b antagonists
JP2024521704A (ja) 2021-05-18 2024-06-04 アドベイト，エルエルシー Ａ２ｂアンタゴニストとしての環状アミド含有ピリジルキサンチン
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
WO2024050825A1 (en) * 2022-09-09 2024-03-14 National Institute Of Biological Sciences, Beijing Compounds as mlkl inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2057752C1 (ru) * 1988-12-22 1996-04-10 Берингер Ингельгейм КГ Производные ксантина в виде смеси изомеров или индивидуальных изомеров, обладающие свойствами антагонистов аденозина

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
AU1507099A (en) * 1997-12-15 1999-07-05 Kyowa Hakko Kogyo Co. Ltd. Preventives/remedies for sleep disturbance
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
AU7962000A (en) * 1999-10-29 2001-05-14 Kyowa Hakko Kogyo Co. Ltd. Us0027324for eating disorders
EP1255550A2 (en) * 2000-02-17 2002-11-13 Cv Therapeutics, Inc. Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
HU229504B1 (hu) * 2001-11-09 2014-01-28 Gilead Sciences A2B-adenozinreceptor-antagonisták
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
KR20040080939A (ko) * 2002-02-01 2004-09-20 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 8-헤테로아릴 크산틴 아데노신 에이투비 수용체 길항제
US7034070B2 (en) * 2002-09-27 2006-04-25 Vincent Chuang Arylalkyl aminofunctional silanes for epoxy laminates
US7148229B2 (en) 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
PT1658291E (pt) 2003-08-25 2013-10-21 Dogwood Pharmaceuticals Inc 8-heteroarilxantinas substituídas
ES2387653T3 (es) 2004-09-01 2012-09-27 Gilead Sciences, Inc. Procedimiento de cicatrización de heridas utilizando antagonistas del receptor de adenosina A2B
RU2391103C2 (ru) 2004-10-15 2010-06-10 Си Ви Терапьютикс, Инк. Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b
US7601723B2 (en) 2005-02-25 2009-10-13 Pgx Health, Llc Pyridyl substituted xanthines
US7579348B2 (en) 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
US7618962B2 (en) 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
CN101198608B (zh) 2005-06-16 2011-04-27 吉利德帕洛阿尔托股份有限公司 A2b腺苷受体拮抗剂的前药
RU2457842C2 (ru) * 2006-03-17 2012-08-10 Гайлид Пало Альто, Инк. Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
BRPI0909157A2 (pt) * 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2057752C1 (ru) * 1988-12-22 1996-04-10 Берингер Ингельгейм КГ Производные ксантина в виде смеси изомеров или индивидуальных изомеров, обладающие свойствами антагонистов аденозина

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUZ'MENKO I I ET AL: "Reactions of theophyllines. Chemical conversions of 8-amino theophyllines". CHEMESTRY OF HETEROCYCLIC COMPOUNDS, vol.36, no.8, 2000, pages 963-970. SEKINE, TOSHIKAZU ET AL: "Dimerizations of. pi.-rich N-heteroaromatic compounds and xanthine derivatives". CHEMICAL AND PHARMACEUTICAL BULLETIN, vol.37, no.8, 1989, pages 1987-1989. *

Also Published As

Publication number Publication date
EP2295434A3 (en) 2011-07-27
WO2005021548A2 (en) 2005-03-10
US20100273780A1 (en) 2010-10-28
BRPI0413922B1 (pt) 2018-08-28
JP4769721B2 (ja) 2011-09-07
PT1658291E (pt) 2013-10-21
DK1658291T3 (da) 2013-10-28
EP1658291B1 (en) 2013-10-02
AU2004268964B2 (en) 2010-03-11
RU2006109474A (ru) 2007-10-10
TWI362390B (en) 2012-04-21
CN101851238B (zh) 2012-07-18
CN1894250B (zh) 2010-06-09
US20050065341A1 (en) 2005-03-24
CN1894250A (zh) 2007-01-10
NZ545715A (en) 2009-02-28
EP2295434A2 (en) 2011-03-16
ES2557310T3 (es) 2016-01-25
EP2295434B1 (en) 2015-09-30
HK1148518A1 (en) 2011-09-09
IL173723A0 (en) 2006-07-05
DK2295434T3 (en) 2015-12-14
ZA200602333B (en) 2007-04-25
TW200524931A (en) 2005-08-01
EP1658291A2 (en) 2006-05-24
AR045499A1 (es) 2005-11-02
US7342006B2 (en) 2008-03-11
US7732455B2 (en) 2010-06-08
CA2536553A1 (en) 2005-03-10
HK1096397A1 (en) 2007-06-01
BRPI0413922A (pt) 2006-10-24
KR20060132549A (ko) 2006-12-21
US20080200456A1 (en) 2008-08-21
AU2004268964A1 (en) 2005-03-10
CA2536553C (en) 2013-01-29
WO2005021548A3 (en) 2005-06-30
IL173723A (en) 2015-01-29
KR101222364B1 (ko) 2013-01-15
CN101851238A (zh) 2010-10-06
BRPI0413922B8 (pt) 2021-05-25
JP2007503443A (ja) 2007-02-22
ES2440467T3 (es) 2014-01-29
PL1658291T3 (pl) 2014-03-31

Similar Documents

Publication Publication Date Title
RU2357969C2 (ru) Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе
US7579348B2 (en) Derivatives of 8-substituted xanthines
US8153628B2 (en) Pyrazolyl substituted xanthines
US7601723B2 (en) Pyridyl substituted xanthines
US8258142B2 (en) Substituted 8-[6-amino-3-pyridyl]xanthines
US20090163491A1 (en) Substituted 8-[6-amino-3pyridyl]xanthines
HK1148518B (en) Substituted 8-heteroaryl xanthines
HK1096397B (en) Substituted 8-heteroaryl xanthines
MXPA06002223A (en) Substituted 8-heteroaryl xanthines

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20110526

PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20211118

PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20211209

PC41 Official registration of the transfer of exclusive right

Effective date: 20211222

PC41 Official registration of the transfer of exclusive right

Effective date: 20220112

PC41 Official registration of the transfer of exclusive right

Effective date: 20220124

PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20220208